Murphy previously worked at the Biotechnology Innovation Organization as its chief policy officer.

The program, Rx-Performance, will be available starting in January of next year.

A new JAMA study indicates that semaglutide produced up to a 68% lower risk of opioid overdose for patients with type 2 diabetes compared to other antidiabetic medications.

Tagrisso was approved under a Priority Review based on the pivotal LAURA Phase III trial in adults with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.

The anti-obesity drug maker is raising awareness about the struggle that constant thoughts about food can have on people trying to manage their weight.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.

The Calliditas Therapeutics CEO discusses her transition from a banker/investor to CEO of a pharma company.

Omnichannel marketing can help companies improve HCP engagement to facilitate the delivery of effective treatment to patients who desperately need and deserve it.

The legal challenges surrounding Biogen’s Aduhelm and Cassava Sciences’ simufilam underscore the ongoing difficulties in Alzheimer's drug development, leading to securities litigation over allegedly misleading statements about trial results and commercialization efforts.

The Octave Bioscience CEO discusses leading the company through commercialization and expansion.

The latest news for pharma industry insiders.

In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, identifies key factors that pharmaceutical and biotech companies should consider when selecting and developing mega campuses.

Max Colao, CEO of OncoVerity, discusses his extensive experience in the biotech industry and shares how his company is harnessing computational biology and machine learning to develop personalized cancer treatments that aim to reshape the future of oncology care.

The latest news for pharma industry insiders.

Atossa Therapeutics’ CEO discusses how the new draft guidance will change the way that many women receive their breast exam results.

In this part of his Pharmaceutical Executive video interview, Jonathan Scheinberg, of the Northeast Science and Technology Center, describes what makes up a mega campus.

The drug is approved for newly diagnosed patients not eligible for transplant and is to be used in combination with standard-of-care treatment.

Bimzelx is the first approved medication for active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis that selectively inhibits IL-17A and IL-17F, both of which are key cytokines that drive inflammatory processes.

The foundation is focused on preventing teen and young adult suicide.

Dr. Cherukuri discusses the impact of Apple’s new AirPods and their ability to be used as hearing aids.

Brian Hillberdink, EVP, LEO Pharma and President of LEO Pharma's US affiliate, discusses their approach to orphan drug development, challenges and opportunities adapting to the US market, and more.

The latest news for pharma industry insiders.

Rybrevant is the first targeted second-line regimen to significantly reduce the risk of disease progression by more than 50% in patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer, according to Johnson & Johnson.

Truxal discusses Exact Science’s first Spanish language TV commercial and campaign for Cologuard.